Thrombocytosis--report of a case.
Thrombocytosis is a common clinical condition. Drugs used for thrombocytosis are hydroxy urea, alkylating agents and interferon alpha. We are reporting a case of chronic myeloid leukemia with thrombocytosis who did not respond to hydroxy urea but was controlled with the addition of a new drug anagrelide. Anagrelide is a platelet reducing agent with no serious side effects. It may be the main weapon against thrombocytosis associated with chronic myeloid leukaemia (CML) and essential thrombocytosis in the coming years.
Department of Internal Medicine and Haematology, Medical College Hospital, Trivandrum-695 011.
M
M
Thomas
K
K
Pavithran
Salil
A
A
Somarajan
D000368:Aged; D000970:Antineoplastic Agents / Q000627:therapeutic use; D005260:Female; D006801:Humans; D006918:Hydroxyurea / Q000627:therapeutic use; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000150:complications / Q000188:drug therapy; D010975:Platelet Aggregation Inhibitors / Q000627:therapeutic use*; D010976:Platelet Count; D011799:Quinazolines / Q000627:therapeutic use*; D013922:Thrombocytosis / Q000188:drug therapy* / Q000209:etiology
D000970:Antineoplastic Agents; D010975:Platelet Aggregation Inhibitors; D011799:Quinazolines; C021139:anagrelide; D006918:Hydroxyurea